JP2024524870A5 - - Google Patents

Info

Publication number
JP2024524870A5
JP2024524870A5 JP2023575640A JP2023575640A JP2024524870A5 JP 2024524870 A5 JP2024524870 A5 JP 2024524870A5 JP 2023575640 A JP2023575640 A JP 2023575640A JP 2023575640 A JP2023575640 A JP 2023575640A JP 2024524870 A5 JP2024524870 A5 JP 2024524870A5
Authority
JP
Japan
Prior art keywords
acid sequence
sequence number
encoded
identity
aforementioned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524870A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032527 external-priority patent/WO2022261113A2/en
Publication of JP2024524870A publication Critical patent/JP2024524870A/ja
Publication of JP2024524870A5 publication Critical patent/JP2024524870A5/ja
Pending legal-status Critical Current

Links

JP2023575640A 2021-06-08 2022-06-07 抗gal3抗体およびインスリン抵抗性に使用する方法 Pending JP2024524870A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202373P 2021-06-08 2021-06-08
US63/202,373 2021-06-08
PCT/US2022/032527 WO2022261113A2 (en) 2021-06-08 2022-06-07 Anti-gal3 antibodies and methods of use for insulin resistance

Publications (2)

Publication Number Publication Date
JP2024524870A JP2024524870A (ja) 2024-07-09
JP2024524870A5 true JP2024524870A5 (https=) 2025-06-17

Family

ID=84426396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575640A Pending JP2024524870A (ja) 2021-06-08 2022-06-07 抗gal3抗体およびインスリン抵抗性に使用する方法

Country Status (5)

Country Link
US (1) US20220411514A1 (https=)
EP (1) EP4352105A4 (https=)
JP (1) JP2024524870A (https=)
CN (1) CN117897406A (https=)
WO (1) WO2022261113A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20220411514A1 (en) * 2021-06-08 2022-12-29 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR099707A1 (es) * 2014-03-10 2016-08-10 La Jolla Pharma Co Composiciones y métodos para tratar trastornos renales
BR112020001698A2 (pt) * 2017-08-03 2020-07-21 Galectin Sciences, Llc compostos para prevenção e tratamento de distúrbios médicos e usos dos mesmos
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) * 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20220411514A1 (en) * 2021-06-08 2022-12-29 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance

Similar Documents

Publication Publication Date Title
JP2024524870A5 (https=)
JP2020169173A5 (https=)
AU2012338733B2 (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
RU2005115477A (ru) Нейтрализующие антитела против gdf-8 и их применение
KR102349370B1 (ko) 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도
JP2021526534A5 (https=)
JP2008529489A5 (https=)
JP2022546454A5 (https=)
JP2023526224A (ja) がんを治療するための、がん治療薬との組合せでの多量体抗dr5結合分子の使用
CN106794233A (zh) 与肺动脉高压的治疗有关的组合物和方法
JP2009519895A5 (https=)
RS64060B1 (sr) Antitelo na anti-adrenomedulin (adm) ili fragment antitela na adm ili struktura antitela na adm bez ig za sprečavanje ili smanjenje disfunkcije organa ili insuficijencije organa kod pacijenta koji ima hroničnu ili akutnu bolest ili akutno stanje
WO2019201133A1 (zh) 神经生长因子的单克隆抗体及其编码基因和应用
JP2024520202A5 (https=)
KR20240040090A (ko) 항-dll3 항체 및 이의 제조 방법, 이의 약물 접합체 및 용도
BR112020005682A2 (pt) monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm)
CN116444667B (zh) 一种靶向gdf15的全人源抗体及其应用
JP2023511963A5 (https=)
CN108431039B (zh) 改进的p2x7受体结合剂和包含其的多肽
JP7210612B2 (ja) 抗aベータ抗体及びその使用
JP7777071B2 (ja) 抗α-シヌクレインモノクローナル抗体およびその使用法
JP2024522076A5 (https=)
CN108484765B (zh) 一种抗人α-防御素-1单克隆抗体及其应用
CN111808196B (zh) 抗pd-1抗体及其用途
WO2018073216A1 (en) Means and methods to treat inflammation